Cytokine-mediated Inflammatory Hyperalgesia Limited by Interleukin-4

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 1999 Mar 2

PMID 10051119

Citations 32

Authors

F Q Cunha

S Poole

B B Lorenzetti

F H Veiga

S H Ferreira

Affiliations

Soon will be listed here.

Abstract

1. The effect of IL-4 on responses to intraplantar (i.pl.) carrageenin, bradykinin, TNFalpha, IL-1beta, IL-8 and PGE2 was investigated in a model of mechanical hyperalgesia in rats. Also, the cellular source of the IL-4 was investigated. 2. IL-4, 30 min before the stimulus, inhibited responses to carrageenin, bradykinin, and TNFalpha, but not responses to IL-1beta, IL-8 and PGE2. 3. IL-4, 2 h before the injection of IL-1beta, did not affect the response to IL-1beta, whereas IL-4, 12 or 12+2 h before the IL-1beta, inhibited the hyperalgesia (-30%, -74%, respectively). 4. In murine peritoneal macrophages, murine IL-4 for 2 h before stimulation with LPS, inhibited (-40%) the production of IL-1beta but not PGE2. Murine IL-4 (for 16 h before stimulation with LPS) inhibited LPS-stimulated PGE2 but not IL-1beta. 5. Anti-murine IL-4 antibodies potentiated responses to carrageenin, bradykinin and TNFalpha, but not IL-1beta and IL-8, as well as responses to bradykinin in athymic rats but not in rats depleted of mast cells with compound 40/80. 6. These data suggest that IL-4 released by mast cells limits inflammatory hyperalgesia. During the early phase of the inflammatory response the mode of action of the IL-4 appears to be inhibition of the production TNFalpha, IL-1beta and IL-8. In the later phase of the response, in addition to inhibiting the production of pro-inflammatory cytokines, IL-4 also may inhibit the release of PGs.

Citing Articles

Interleukin-4 Induces the Release of Opioid Peptides from M1 Macrophages in Pathological Pain.

Labuz D, Celik M, Seitz V, Machelska H J Neurosci. 2021; 41(13):2870-2882.

PMID: 33593854 PMC: 8018889. DOI: 10.1523/JNEUROSCI.3040-20.2021.

IL-4 induces M2 macrophages to produce sustained analgesia via opioids.

Celik M, Labuz D, Keye J, Glauben R, Machelska H JCI Insight. 2020; 5(4).

PMID: 32102987 PMC: 7101153. DOI: 10.1172/jci.insight.133093.

Advanced Technology for Gene Delivery with Homing Peptides to Spinal Cord through Systemic Circulation in Mice.

Terashima T, Ogawa N, Sato T, Katagi M, Nakae Y, Okano J Mol Ther Methods Clin Dev. 2019; 13:474-483.

PMID: 31193742 PMC: 6538929. DOI: 10.1016/j.omtm.2019.04.008.

Chronic Pain in Inflammatory Arthritis: Mechanisms, Metrology, and Emerging Targets-A Focus on the JAK-STAT Pathway.

Salaffi F, Giacobazzi G, Di Carlo M Pain Res Manag. 2018; 2018:8564215.

PMID: 29623147 PMC: 5829432. DOI: 10.1155/2018/8564215.

Targeting Cytokines for Morphine Tolerance: A Narrative Review.

Liu D, Zhou Y, Gao F Curr Neuropharmacol. 2017; 17(4):366-376.

PMID: 29189168 PMC: 6482476. DOI: 10.2174/1570159X15666171128144441.

References

Elias J, Lentz V, Cummings P . Transforming growth factor-beta regulation of IL-6 production by unstimulated and IL-1-stimulated human fibroblasts. J Immunol. 1991; 146(10):3437-43. View

Dinarello C . Interleukin-1 and interleukin-1 antagonism. Blood. 1991; 77(8):1627-52. View

Cunha F, Lorenzetti B, Poole S, Ferreira S . Interleukin-8 as a mediator of sympathetic pain. Br J Pharmacol. 1991; 104(3):765-7. PMC: 1908235. DOI: 10.1111/j.1476-5381.1991.tb12502.x. View

Vannier E, Miller L, Dinarello C . Coordinated antiinflammatory effects of interleukin 4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist. Proc Natl Acad Sci U S A. 1992; 89(9):4076-80. PMC: 525635. DOI: 10.1073/pnas.89.9.4076. View

Fenton M, Buras J, Donnelly R . IL-4 reciprocally regulates IL-1 and IL-1 receptor antagonist expression in human monocytes. J Immunol. 1992; 149(4):1283-8. View

Cunha F, Poole S, Lorenzetti B, Ferreira S . The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia. Br J Pharmacol. 1992; 107(3):660-4. PMC: 1907751. DOI: 10.1111/j.1476-5381.1992.tb14503.x. View

Cunha F, Boukili M, da Motta J, Vargaftig B, Ferreira S . Blockade by fenspiride of endotoxin-induced neutrophil migration in the rat. Eur J Pharmacol. 1993; 238(1):47-52. DOI: 10.1016/0014-2999(93)90503-a. View

Cassatella M, Meda L, Bonora S, Ceska M, Constantin G . Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by.... J Exp Med. 1993; 178(6):2207-11. PMC: 2191270. DOI: 10.1084/jem.178.6.2207. View

Ferreira S, Lorenzetti B, Poole S . Bradykinin initiates cytokine-mediated inflammatory hyperalgesia. Br J Pharmacol. 1993; 110(3):1227-31. PMC: 2175796. DOI: 10.1111/j.1476-5381.1993.tb13946.x. View

10.

Seitz M, Loetscher P, DEWALD B, Towbin H, Ceska M, Baggiolini M . Production of interleukin-1 receptor antagonist, inflammatory chemotactic proteins, and prostaglandin E by rheumatoid and osteoarthritic synoviocytes--regulation by IFN-gamma and IL-4. J Immunol. 1994; 152(4):2060-5. View

11.

Tunon de Lara J, Okayama Y, McEUEN A, Heusser C, Church M, Walls A . Release and inactivation of interleukin-4 by mast cells. Ann N Y Acad Sci. 1994; 725:50-8. DOI: 10.1111/j.1749-6632.1994.tb39789.x. View

12.

Watkins L, Wiertelak E, Goehler L, Smith K, Martin D, Maier S . Characterization of cytokine-induced hyperalgesia. Brain Res. 1994; 654(1):15-26. DOI: 10.1016/0006-8993(94)91566-0. View

13.

Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W . Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci U S A. 1994; 91(25):12013-7. PMC: 45366. DOI: 10.1073/pnas.91.25.12013. View

14.

Rankin E, Choy E, Kassimos D, Kingsley G, Sopwith A, Isenberg D . The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol. 1995; 34(4):334-42. DOI: 10.1093/rheumatology/34.4.334. View

15.

Poole S, Cunha F, Selkirk S, Lorenzetti B, Ferreira S . Cytokine-mediated inflammatory hyperalgesia limited by interleukin-10. Br J Pharmacol. 1995; 115(4):684-8. PMC: 1908480. DOI: 10.1111/j.1476-5381.1995.tb14987.x. View

16.

Watkins L, Goehler L, Relton J, Brewer M, Maier S . Mechanisms of tumor necrosis factor-alpha (TNF-alpha) hyperalgesia. Brain Res. 1995; 692(1-2):244-50. DOI: 10.1016/0006-8993(95)00715-3. View

17.

Endo T, OGUSHI F, Sone S . LPS-dependent cyclooxygenase-2 induction in human monocytes is down-regulated by IL-13, but not by IFN-gamma. J Immunol. 1996; 156(6):2240-6. View

18.

Callard R, Matthews D, Hibbert L . IL-4 and IL-13 receptors: are they one and the same?. Immunol Today. 1996; 17(3):108-10. DOI: 10.1016/0167-5699(96)80600-1. View

19.

Lord C, Lamb J . TH2 cells in allergic inflammation: a target of immunotherapy. Clin Exp Allergy. 1996; 26(7):756-65. View

20.

Stefferl A, Hopkins S, Rothwell N, Luheshi G . The role of TNF-alpha in fever: opposing actions of human and murine TNF-alpha and interactions with IL-beta in the rat. Br J Pharmacol. 1996; 118(8):1919-24. PMC: 1909906. DOI: 10.1111/j.1476-5381.1996.tb15625.x. View